In that particular session, Stock kicked-off at the price of $13.66 while reaching the peak value of $14.18 and lowest value recorded on the day was $13.11. Get Black Diamond Therapeutics Inc (BDTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely. Black Diamond Therapeutics' last funding round was on Jan 2020 for a total of $201.1M The Cambridge, Massachusetts -based company said it had a loss of 84 cents per share. Black Diamond Therapeutics Inc (BDTX) stock is trading at $23.67 as of 2:13 PM on Tuesday, May 18, a loss of -$1.39, or -5.57% from the previous closing price of $25.06. Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET CAMBRIDGE, Mass. Get the hottest stocks to … In its first day of trading, the cancer drug developer watched its shares soar more than 108 percent. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Black Diamond Therapeutics Inc is a precision oncology medicine company. Black Diamond ended the first quarter of 2021 with $290.1 million in cash, cash equivalents, and investments compared to $357.2 million as of March 31, 2020. Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting finance.yahoo.com - March 10 at 7:38 PM Black Diamond Therapeutics, Inc. It is understandable that investor optimism is growing ahead of the company’s current quarter results. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors.Dr. Financial Highlights. Industry: Biotechnology. Black Diamond Therapeutics Inc. [NASDAQ: BDTX] stock went on a downward path that fall over -3.89% on Tuesday, amounting to a one-week price decrease of less than -7.42%. Get the latest Black Diamond Therapeutics, Inc (BDTX) stock news and headlines to help you in your trading and investing decisions. Black Diamond Therapeutics initiated at outperform with $45 price target at Wedbush MarketWatch… CAMBRIDGE, Mass. Three analysts have made estimates for Black Diamond Therapeutics’ earnings, with the lowest sales estimate coming in at $797.10 million and the highest estimate coming in at $800.75 million. Black Diamond Therapeutics was the first company to emerge from Ridgeline, Versant Ventures’ Discovery Engine based in the Basel Technology Park. Institutional Ownership. Black Diamond Therapeutics (BDTX) has an average rating of buy and price targets ranging from $24 to … Data delayed 15 minutes ... U.S. News has analyzed over 4,500 stocks to help investors reach their financial goals. During the recent session, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)’s traded shares were 5,574,392, with the beta value of the company hitting 0. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond Therapeutics Inc (BDTX) stock is lower by -2.75% while the S&P 500 is higher by 0.13% as of 11:25 AM on Thursday, Jan 21. Black Diamond Therapeutics is leading the way, having raised $201 million from its IPO. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors. Company Summary. Net cash used in operations was $24.5 million for the first quarter … ... U.S. News … In that particular session, Stock kicked-off at the price of $13.66 while reaching the peak value of $14.18 and lowest value recorded on the day was $13.11. So it had a … Over the past year the S&P 500 is up 17.45% while BDTX is down -33.61%. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Black Diamond Therapeutics, Inc. is an equal opportunity employer. The company report on January 5, 2021 that Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Confe The company, currently valued at $484.58 Million, closed the last trade at $13.4 per share which meant it lost -$0.53 on the day or … Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. We would like to show you a description here but the site won’t allow us. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) has completed its initial public offering (IPO) on NASDAQ, raising US $201 million through the issuance of 10.6 million shares at US $19 per share. The stock current value is … Share Price & News. Startups, BioPharma. CAMBRIDGE, Mass. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond Therapeutics (NASDAQ: BDTX) shares have tumbled nearly 30% in premarket trading after the company posted early-stage results of … Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, MasterKey Therapies. Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET. Black Diamond Therapeutics plans to list on the Nasdaq, the exchange of choice for most biotechs. Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast presentation on Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and preliminary efficacy data from the Phase 1 Black Diamond Therapeutics Inc stock is down -39.93% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives BDTX stock a score of 33 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 3. The 52-week high for the BDTX s Black Diamond Therapeutics Inc. [NASDAQ: BDTX] stock went on a downward path that fall over -14.79% on Tuesday, amounting to a one-week price decrease of less than -6.86%. Black Diamond Therapeutics Inc. $12.83 +1.34%. Volume … H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report) today and set a price target of $53.00.The company’s shares closed last Wednesday at $22.23, close to its 52-week low of $21.04. News Headlines for Black Diamond Therapeutics Inc. Thursday, Jan 07, 2021. Black Diamond Therapeutics Inc. (NASDAQ:BDTX) went down by -28.48% from its latest closing price compared to the recent 1-year high of $46.25. Free real-time prices, trades, and chat. Its drugs under pipeline are BDTX-189 and BDTX-1535 Mar 25, 2021. If you are a California consumer, you have the right, at any time, to direct a business that sells your personal information to third parties to not sell your personal information. Black Diamond pioneered the development of selective medicines for … Black Diamond Therapeutics Inc. is an oncology medicine company. Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. About Black Diamond Therapeutics. Black Diamond Therapeutics Inc is a precision oncology medicine company. Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Black Diamond Therapeutics Inc (BDTX) InvestorPlace 5/20/2021. Wall Street brokerages predict that Black Diamond Therapeutics (NASDAQ:REYN) will announce $798.38 million in sales for the current quarter, Zacks reports. May 7, 2021. May 7, 2021. CAMBRIDGE, Mass. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. CAMBRIDGE, Mass. Black Diamond Therapeutics, Inc. stock news. That single transaction was for US$152k worth of shares at a price of US$30.46 each. Black Diamond Therapeutics, Inc. is a precision oncology medicine company. CAMBRIDGE, Mass. Latest Share Price and Events. Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth … That single transaction was for US$152k worth of shares at a price of US$30.46 each. ET by Ciara Linnane. Black Diamond Therapeutics, Inc.Condensed Consolidated Balance Sheet Data (Unaudited)(in thousands) March 31,2021 December 31,2020Cash, cash equivalents, and investments$290,055 $315,067 Total assets$313,259 $329,670 Accumulated deficit$(148,525) $(118,224) Total stockholders’ equity$280,753 $307,758 Black Diamond Therapeutics, … That means that an insider was happy to buy shares at above the current price of US$24.16. Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Earlier, BDTX’s stock lost 4.63% to close Wednesday’s normal session at $22.23 per share. Black Diamond Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.50, which is a 106.2% upside from current levels. 180 Varick Street, 6th Floor New York, NY 10014. Feb 2, 2021. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has a beta value of 0 and has seen 4,051,846 shares traded in the last trading session. 02/03/2020. Black Diamond Therapeutics Inc stock is down -65.90% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives BDTX stock a score of 29 out of a possible 100.. That rank is mainly influenced by a short-term technical score of 0. In March 2020, Black Diamond Therapeutics had US$357m in cash, and was debt-free. The stock has traded between $23.66 and $26.43 so far today. and NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Job Listings You can view all open positions or use the following search form to find jobs that suit your specific career interests. BDTX is down -$0.74 from the previous closing price of $26.95 on volume of 210,594 shares. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Corporate Headquarters One Main Street, 10th Floor Cambridge, MA 02142. Black Diamond Therapeutics plans to list on the Nasdaq, the exchange of choice for most biotechs. Black Diamond Therapeutics said in its filings that it plans to use the IPO proceeds to develop its BDTX-189 cancer medicine, with a combined phase 1/2 clinical trial starting in … Black Diamond Therapeutics to offer 8.9 million shares in planned IPO, priced at $16 to $18 each. Versant Ventures today announced that Black Diamond Therapeutics completed an IPO on NASDAQ, raising $201 million through the sale of 10.6 million sha Get Black Diamond Therapeutics Inc (BDTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Black Diamond ended the first quarter of 2021 with $290.1 million in cash, cash equivalents, and investments compared to $357.2 million as of March 31, 2020. About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond Therapeutics Inc. (BDTX) Analyst Forecasts. CAMBRIDGE, Mass. To access the presentation, please … Black Diamond Therapeutics Inc., which has a market valuation of $474.39 million. The company’s stock price has collected -20.18% of loss in the last five trading sessions. About Black Diamond Therapeutics. May 7, 2021 . CAMBRIDGE, Mass. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) insider Brent Hatzis-Schoch sold 4,078 shares of the company’s stock in a transaction dated Monday, April 12th. The … Since Black Diamond Therapeutics was founded in 2016, it has participated in 6 rounds of funding. Explore commentary on Black Diamond Therapeutics… A live webcast presentation will be available on the News & Events section of the Black Diamond website at www.blackdiamondtherapeutics.com. The company report on January 5, 2021 that Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Confe Black Diamond Therapeutics Inc. (BDTX) shares plunged 18.58% to trade at $18.1 in the after-market on Wednesday, May 19, 2021. Find real-time BDTX - Black Diamond Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The Last 12 Months Of Insider Transactions At Black Diamond Therapeutics. The most recent transaction is an insider sale by Hatzis-Schoch Brent. At the end of the latest market close, Black Diamond Therapeutics Inc. (BDTX) was valued at $13.65. In total Black Diamond Therapeutics has raised $408.2M. That means that an insider was happy to buy shares at above the current price of US$24.16. The shares were sold at an average price of $25.00, for a total transaction of $101,950.00. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash.
Missing 4 Notes Mad Monster Mansion, Spicy Tuna Crispy Rice Near Me, Central Park Tennis Arsenal, Soto Windmaster Stove Canada, Cambridge City Christmas Lights, Intensive Therapy Weekend, Bally Supersonic Pinball Machine Parts, How To Pronounce Zeke Jaeger,